Imatinib mesylate is a 2-phenylamino-pyrimidine derivative protein and tyrosine kinase inhibitor initially targeted to the platelet-derived growth factor receptor.

Blocking this constitutive action has been shown to induce downstream apoptosis without further differentiation.